Abstract
In patients with advanced stages of peripheral arterial occlusive disease, the increasing perfusion of ischemic skin is of particular therapeutic significance. In several clinical studies [10, 12, 18], an increase in the transcutaneous oxygen pressure could be observed after intravenous prostaglandin Ex infusion. The present study investigated the question of whether the transcutaneous oxygen pressure can also be improved in selected patients with very low pressures and thus a poor initial situation. Moreover, the dose dependency of this parameter was investigated.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Alexander K (1975) Gefäßkrankheiten. Steinkopf, Stuttgart, p 75
Caspary L, Creutzig A, Alexander K (1987) Reaction of transcutaneous PO2 and laser Doppler flow signal on intraarterial infusion of PGE1 and nucleotide phosphates in patients with peripheral arterial occlusive disease. Vasa Suppl 17: 17–22
Caspary L, Creutzig A, Alexander K (1988) Wirkung intraarterieller Infusionen auf den VorfuB tcPO2 bei Patienten mit arterieller Verschlußkrankheit. Vasa Suppl 23: 54–56
Creutzig A, Caspary L, Alexander K (1987) Transcutaneous oxygen pressure measured at two different electrode core temperatures in healthy volunteers and patients with arterial occlusive disease. Int J Microcirc Clin Exp 5: 373–378
Creutzig A (1991) Evaluation of pharmacologic effects. In: Belcaro G, Bollinger A, Nicolaides AN, Hoffmann U (eds) Progress in the evaluation of the microcirculation by laser Doppler flowmetry. Med Orion, London (in press)
Creutzig A, Caspary L, Alexander K (1990) Skin surface oxygen pressure fields during administration of prostaglandin E1 in patients with arterial occlusive disease. Klin Wochenschr 68: 207–212
Creutzig A, Caspary L, Alexander K (1991) Skin surface oxygen pressure in healthy volunteers and patients with arterial occlusive disease. Int J Microcirc Clin Exp 10: 231–240
Creutzig A, Caspary L, Ranke C, Kiessling D, Wilkens J, Frölich J, Alexander K (1987) Transkutaner PO2 and Laser Doppler Flux bei steigenden Dosierungen von intraarteriell und intravenös appliziertem Prostaglandin E1. Vasa 16: 114–118
Creutzig A, Lux M, Alexander K (1984) Muscle tissue oxygen pressure fields and transcutaneous oxygen pressure in healthy men during intra-arterial prostaglandin E1 infusion. Int Angiol 3: 105–110
Ehrly AM, Schenk J, Saeger-Lorenz K (1987) Einfluß einer intravenösen Gabe von Prostaglandin E1 auf den Muskelgewebesauerstoffdruck, die transkutanen Gasdruckwerte und die Fließeigenschaften des Blutes von Patienten im Stadium III und IV der chronischen arteriellen Verschlußkrankheit. Vasa Suppl 20: 196–198
Fagrell B, Lundberg G, Olsson A, Östergren J (1986) PGE1 treatment of severe skin ischemia in patients with peripheral insufficiency - the effect on skin microcirculation. Vasa 15: 56–60
Heidrich H, Lammersen T (1985) Vitalkapillarmikroskopische Untersuchungen und transkutane PO2-Messungen bei intravenoser Prostaglandin-E1-Infusion. Dtsch Med Wochenschr 110: 1283–1285
Jogestrand T, Olsson AG (1985) The effect of intravenous prostaglandin E1 in ischaemic pain and on leg blood-flow in subjects with peripheral artery disease: a double-blind controlled study. Clin Physiol 5: 495–502
Ranke C, Creutzig A, Alexander K (1991) Hämodynamische Effekte einer intermittierenden intraarteriellen Infusionsbehandlung mit Prostaglandin E1 bei peripherer arterieller Verschlußkrankheit. Med Klin 86: 349–352
Rieger H, Scheffler A (1987) Fluoreszenzangiographische Befunde nach intravenoser und intraarterieller Infusion von Prostaglandin E1(PGE1) bei Kranken mit arterieller VerschluBkrankheit (AVK) im Stadium II. Vasa Suppl 20: 212–214
Rieger H, Scheffler A (1988) Fluoreszenzangiographische Befunde nach intravenoser und intraarterieller Infusion von Prostaglandin E1(PGE1) bei Kranken mit arterieller Verschlußkrankheit (AVK) im Stadium II. In: Heinrich H, Böhme W, Rogatti W (ed) Prostaglandin E1.Wirkungen und therapeutische Wirksamkeit. Springer, Berlin Heidelberg New York, p 66
Rudofsky G (1987) Beeinflussung der Kollateralarterien durch i. a.-Prostaglandin E1- Infusion. Vasa Suppl 20: 215–217
Scheffler A, Rieger H (1990) Akrale Hautdurchblutungen nach intraarterieller Infusion gefäßerweiternder Substanzen bei Patienten mit Claudicatio intermittens. Med Klin 85: 1–5
Scheffler P, De La Hamette D, Leipnitz G (1989) Therapeutic efficacy of intravenously applied prostaglandin E1. Vasa Suppl 28: 19–25
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1991 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Creutzig, A., Caspary, L., Alexander, K. (1991). Transcutaneous Oxygen Pressure at Different Dosages of Intravenous Prostaglandin E1 in Patients with Severe Arterial Occlusive Disease: A Double-Blind, Placebo-Controlled Study. In: Diehm, C., Sinzinger, H., Rogatti, W. (eds) Prostaglandin E1 . Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-76910-8_9
Download citation
DOI: https://doi.org/10.1007/978-3-642-76910-8_9
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-54524-8
Online ISBN: 978-3-642-76910-8
eBook Packages: Springer Book Archive